The impact of routine cryptococcal antigen screening on survival among HIV-infected individuals with advanced immunosuppression in Kenya

Tropical Medicine and International Health

Volumn 18, Issue 4, 2013, Pages 495-503

  Meyer, A C L ^a,b   Kendi, C K ^a   Penner, J A ^a,c   Odhiambo, N ^a   Otieno, B ^a   Omondi, E ^a   Opiyo, E ^a   Bukusi, E A ^a   Cohen, C R ^b  

^a KENYA MEDICAL RESEARCH INSTITUTE   (Kenya)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Africa; Cryptococcal meningitis; Cryptococcus; Outcomes; Prevention; Screening

Indexed keywords

CRYPTOCOCCAL ANTIGEN; FLUCONAZOLE; FUNGUS ANTIGEN; UNCLASSIFIED DRUG;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIGEN; BACTERIUM; DISEASE TREATMENT; DRUG; EPIDEMIOLOGY; FUNGAL DISEASE; HUMAN IMMUNODEFICIENCY VIRUS; HYPOTHESIS TESTING; MENINGITIS; MORTALITY; SERUM; SURVIVAL; WOMENS HEALTH;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; CONTROLLED STUDY; CRYPTOCOCCOSIS; DRUG MEGADOSE; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; IMMUNE DEFICIENCY; KENYA; MAJOR CLINICAL STUDY; MALE; MORTALITY; OVERALL SURVIVAL; SURVIVAL RATE;

ADULT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTI-RETROVIRAL AGENTS; ANTIFUNGAL AGENTS; ANTIGENS, FUNGAL; CASE-CONTROL STUDIES; CD4 LYMPHOCYTE COUNT; CRYPTOCOCCUS NEOFORMANS; FEMALE; FLUCONAZOLE; HUMANS; KAPLAN-MEIER ESTIMATE; KENYA; MALE; MENINGITIS, CRYPTOCOCCAL; SURVIVAL RATE; TREATMENT OUTCOME;

KENYA;

EID: 84875242783     PISSN: 13602276     EISSN: 13653156     Source Type: Journal    
DOI: 10.1111/tmi.12067     Document Type: Article

References (24)

1. Bicanic T, Muzoora C, Brouwer AE et al. (2009) Independent Association between Rate of Clearance of Infection and Clinical Outcome of HIV-Associated Cryptococcal Meningitis: analysis of a Combined Cohort of 262 Patients. Clinical infectious diseases 49, 702-9.
2. Chariyalertsak S, Sirisanthana T, Saengwonloey O & Nelson KE (2001) Clinical presentation and risk behaviors of patients with acquired immunodeficiency syndrome in Thailand, 1994-1998: regional variation and temporal trends. Clinical Infectious Diseases 32, 955-962.
3. Collett G & Parrish A (2007) Fluconazole donation and outcomes assessment in cryptococcal meningitis. South African Medical Journal 97, 175-176.
4. French N, Gray K, Watera C et al. (2002) Cryptococcal infection in a cohort of HIV-1-infected Ugandan adults. AIDS 16, 1031-1038.
5. Jackson A & van der Horst C (2012) New insights in the prevention, diagnosis and treatment of cryptococcal meningitis. Current HIV/AIDS reports 9, 267-277.
6. Jarvis J, Lawn S, Vogt M, Bangani N, Wood R & Harrison T (2009) Screening for cryptococcal antigenemia in patients accessing an antiretroviral treatment program in South Africa. Clinical Infectious Diseases 48, 856-862.
7. Jarvis J, Percival A, Bauman S et al. (2011) Evaluation of a novel point-of-care cryptococcal antigen test on serum, plasma, and urine from patients with HIV-associated cryptococcal meningitis. Clinical Infectious Diseases 53, 1019-1023.
8. Kendi C, Penner J, Koech J et al. (2012) Predictors of outcome in routine care for Cryptococcal meningitis in Western Kenya: lessons for HIV outpatient care in resource-limited settings. Postgraduate Medical Journal 1-5.
9. Lawn S, Harries A, Anglaret X, Myer L & Wood R (2008) Early mortality among adults accessing antiretroviral treatment programmes in sub-Saharan Africa. AIDS 22, 1897-1908.
10. Liechty CA, Solberg P, Were W et al. (2007) Asymptomatic serum cryptococcal antigenemia and early mortality during antiretroviral therapy in rural Uganda. Tropical medicine & international health 12, 929-935.
11. Lindsley M, Mekha N, Baggett H et al. (2011) Evaluation of a newly developed lateral flow immunoassay for the diagnosis of cryptococcosis. Clinical Infectious Diseases 53, 321-325.
12. Longley N, Muzoora C, Taseera K et al. (2008) Dose response effect of high-dose fluconazole for HIV-associated cryptococcal meningitis in southwestern Uganda. Clinical Infectious Diseases 47, 1556-1561.
13. McCarthy KM, Morgan J, Wannemuehler KA et al. (2006) Population-based surveillance for cryptococcosis in an antiretroviral-naive South African province with a high HIV seroprevalence. AIDS 20, 2199-2206.
14. Menichetti F, Fiorio M, Tosti A et al. (1996) High-dose fluconazole therapy for cryptococcal meningitis in patients with AIDS. Clinical infectious diseases 22, 838-840.
15. Meya DB, Manabe YC, Castelnuovo B et al. (2010) Cost-effectiveness of serum cryptococcal antigen screening to prevent deaths among HIV-infected persons with a CD4 + cell count < or = 100 cells/microL who start HIV therapy in resource-limited settings. Clinical Infectious Diseases 51, 448-455.
16. Micol R, Lortholary O, Sar B et al. (2007) Prevalence, determinants of positivity, and clinical utility of cryptococcal antigenemia in Cambodian HIV-infected patients. Journal of Acquired Immune Deficiency Syndromes 45, 555-559.
17. Mwaba P, Mwansa J, Chintu C et al. (2001) Clinical presentation, natural history, and cumulative death rates of 230 adults with primary cryptococcal meningitis in Zambian AIDS patients treated under local conditions. Postgraduate Medical Journal 77, 769-773.
18. Nelson MR, Bower M, Smith D, Reed C, Shanson D & Gazzard B (1990) The value of serum cryptococcal antigen in the diagnosis of cryptococcal infection in patients infected with the human immunodeficiency virus. Journal of Infection 21, 175-181.
19. Park B, Wannemuehler K, Marston B, Govender N, Pappas P & Chiller T (2009) Estimation of the current global burden of cryptococcal meningitis among persons living with HIV/AIDS. AIDS 23, 525.
20. Pongsai P, Atamasirikul K & Sungkanuparph S (2010) The role of serum cryptococcal antigen screening for the early diagnosis of cryptococcosis in HIV-infected patients with different ranges of CD4 cell counts. Journal of Infection. 60, 474-477.
21. Tansuphasawadikul S, Amornkul PN, Tanchanpong C et al. (1999) Clinical presentation of hospitalized adult patients with HIV infection and AIDS in Bangkok, Thailand. Journal of acquired immune deficiency syndromes 21, 326-332.
22. The Antiretroviral Therapy in Lower Income Countries (ART-LINC) Collaboration, ART Cohort Collaboration (ART-CC) group (2006) Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries. Lancet 367, 817-824.
23. Wajanga B, Kalluvya S, Downs J, Johnson W, Fitzgerald D & Peck R (2011) Universal screening of Tanzanian HIV-infected adult inpatients with the serum cryptococcal antigen to improve diagnosis and reduce mortality: an operational study. Journal of the International AIDS Society 14, 48.
24. World Health Organization (2011) Rapid advice: diagnosis, prevention and management of cryptococcal disease in HIV-infected adults, adolescents and children. World Health Organization, Geneva, Switzerland.